TLR7激动剂与沙门氏菌联合作为一种有效的抗黑色素瘤免疫疗法。
TLR7 agonist in combination with Salmonella as an effective antimelanoma immunotherapy.
作者信息
Vola Magdalena, Mónaco Amy, Bascuas Thais, Rimsky Geraldine, Agorio Caroline Isabel, Chabalgoity José Alejandro, Moreno María
机构信息
Departamento de Desarrollo Biotecnológico, Instituto de Higiene. Facultad de Medicina, Universidad de la República. Av. A. Navarro 3051, Montevideo, CP 11600, Uruguay.
Cátedra de Dermatología, Hospital de Clínicas 'Dr. Manuel Quintela'. Facultad de Medicina, Universidad de la República. Av. Italia s/n, Montevideo, Uruguay.
出版信息
Immunotherapy. 2018 Jun;10(8):665-679. doi: 10.2217/imt-2017-0188. Epub 2018 Mar 22.
AIM
We evaluated a novel approach combining the use of attenuated Salmonella immunotherapy with a Toll-like receptor agonist, imiquimod, in B16F1 melanoma-bearing mice.
MATERIALS & METHODS: B16F1 melanoma-bearing mice were daily treated with topical imiquimod in combination with one intratumoral injection of attenuated Salmonella enterica serovar Typhimurium LVR01.
RESULTS
The combined therapy resulted in retarded tumor growth and prolonged survival. Combination treatment led to an enhancement in the expression of pro-inflammatory cytokines and chemokines in the tumor microenvironment, with a Th1-skewed profile, resulting in a broad antitumor response. The induced immunity was effective in controlling the occurrence of metastasis.
CONCLUSION
Salmonella LVR01 immunotherapy in combination with imiquimod is a novel approach that could be considered as an effective antimelanoma therapy.
目的
我们评估了一种将减毒沙门氏菌免疫疗法与Toll样受体激动剂咪喹莫特联合使用的新方法，用于患有B16F1黑色素瘤的小鼠。
材料与方法
对患有B16F1黑色素瘤的小鼠每天进行局部咪喹莫特治疗，并瘤内注射一次减毒肠炎沙门氏菌血清型鼠伤寒沙门氏菌LVR01。
结果
联合治疗导致肿瘤生长迟缓，生存期延长。联合治疗使肿瘤微环境中促炎细胞因子和趋化因子的表达增强，呈现Th1型偏向，从而产生广泛的抗肿瘤反应。诱导的免疫对控制转移的发生有效。
结论
沙门氏菌LVR01免疫疗法与咪喹莫特联合使用是一种可被视为有效的抗黑色素瘤治疗的新方法。
Zotero 插件